{"id":"W2495752760","doi":"10.1186/s13063-016-1466-2","title":"Subcutaneous immunoglobulin for maintenance treatment in chronic inflammatory demyelinating polyneuropathy (The PATH Study): study protocol for a randomized controlled trial","year":2016,"lang":"en","type":"article","venue":"Trials","topic":"Peripheral Neuropathies and Disorders","field":"Medicine","cited_by":24,"is_retracted":false,"has_abstract":true,"ca_institutions":"University of Toronto; University Health Network","funders":"UCB Pharma; Seventh Framework Programme; Genentech; Grifols; GBS/CIDP Foundation International; Glenmark Pharmaceuticals; Myasthenia Gravis Foundation of America; AstraZeneca; CSL Behring; Argenx; GlaxoSmithKline; European Commission; Acorda Therapeutics; Pfizer","keywords":"Medicine; Chronic inflammatory demyelinating polyneuropathy; Randomized controlled trial; Protocol (science); Antibody; Immunology; Physical therapy; Bioinformatics; Internal medicine; Pathology; Alternative medicine","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.03731906,0.008279463,0.01255054,0.002136399,0.003424933,0.004258886,0.003790548,0.007852964,0.06591717],"category_scores_gemma":[0.0272016,0.003129637,0.004569631,0.003356124,0.004374224,0.003714647,0.002076042,0.008339137,0.01269715],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.004701412,"about_ca_system_score_gemma":0.01510712,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001558774,"about_ca_topic_score_gemma":0.003657178,"domain_scores_codex":[0.976647,0.01503939,0.002121221,0.001893611,0.001985261,0.002313516],"domain_scores_gemma":[0.9881386,0.00305143,0.002761094,0.001549395,0.002372829,0.002126612],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"not_applicable","study_design_scores_codex":[0.9275599,0.009811668,0.0006660817,0.0196124,0.001856505,0.0002171434,0.0002538686,0.001476757,0.002088032,0.00370757,0.0137823,0.01896771],"study_design_scores_gemma":[0.9572089,0.01723146,0.0009715568,0.002058614,0.0006440199,0.00004297133,0.00005871355,0.001073105,0.0003721867,0.001182586,0.01909426,0.00006156849],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"protocol","genre_gemma":"protocol","genre_scores_codex":[0.001822019,0.0004756534,0.001272043,0.0001981979,0.0003917158,0.9940997,0.0009557286,0.00009604034,0.0006888294],"genre_scores_gemma":[0.002050232,0.0002305697,0.001681083,0.0001916585,0.00008652576,0.9951935,0.0001921044,0.000006890265,0.0003672598],"genre_candidate":"protocol","genre_consensus":"protocol","teacher_disagreement_score":0.06591717,"threshold_uncertainty_score":0.2205149,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.04971943532551758,"score_gpt":0.3810367955733524,"score_spread":0.3313173602478348,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}